EFFICACY OF ACCELERATED STREPTOKINASE INFUSION IN THE TREATMENT OF ST ELEVATION MYOCARDIAL INFARCTION

IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Umer Shafiq, Muhammad Abdul Wahab, S. Rahman
{"title":"EFFICACY OF ACCELERATED STREPTOKINASE INFUSION IN THE TREATMENT OF ST ELEVATION MYOCARDIAL INFARCTION","authors":"Umer Shafiq, Muhammad Abdul Wahab, S. Rahman","doi":"10.47144/phj.v55isupplement1.2419","DOIUrl":null,"url":null,"abstract":"Objectives: Cardiovascular disease (CVD) is considered as one of the important priorities in the health systems of all countries. Approximately 550,000 first episodes and 200,000 recurrent episodes of acute myocardial infarction occur annually worldwide. Globally, ischemic heart disease has become the leading contributor to the burden of disease as assessed on the basis of disability-adjusted life-years. To determine the efficacy of accelerated streptokinase in patients with acute ST elevation myocardial infarction. \nMethodology: This Descriptive study was done in the Department of Cardiology, Hayatabad Medical Complex Peshawar from August 2020 to February 2021. Total 144 patients were observed. All patients were subjected to SK in a dose of 1.5million units over 60 minutes. All patients were under strict observation and a repeat ECG was performed to determine the efficacy of accelerated SK. \nResults: Our study shows that among 144 patients mean age and standard deviation was 61± 8.19. 88(61%) patients were male and 56(39%) patients were female. More over accelerated streptokinase was effective in 92(64%) patients and was not effective in 52(36%) patients. \nConclusion: The accelerated SK infusion regimen of 1.5 MU in 20 min is safe and well tolerated with significantly faster and higher clinical reperfusion rates, more preserved LV systolic function, less atrial and ventricular sustained arrhythmias, and less in-hospital and 1 year mortality rates in acute STEMI.","PeriodicalId":42273,"journal":{"name":"Pakistan Heart Journal","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Heart Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47144/phj.v55isupplement1.2419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Cardiovascular disease (CVD) is considered as one of the important priorities in the health systems of all countries. Approximately 550,000 first episodes and 200,000 recurrent episodes of acute myocardial infarction occur annually worldwide. Globally, ischemic heart disease has become the leading contributor to the burden of disease as assessed on the basis of disability-adjusted life-years. To determine the efficacy of accelerated streptokinase in patients with acute ST elevation myocardial infarction. Methodology: This Descriptive study was done in the Department of Cardiology, Hayatabad Medical Complex Peshawar from August 2020 to February 2021. Total 144 patients were observed. All patients were subjected to SK in a dose of 1.5million units over 60 minutes. All patients were under strict observation and a repeat ECG was performed to determine the efficacy of accelerated SK. Results: Our study shows that among 144 patients mean age and standard deviation was 61± 8.19. 88(61%) patients were male and 56(39%) patients were female. More over accelerated streptokinase was effective in 92(64%) patients and was not effective in 52(36%) patients. Conclusion: The accelerated SK infusion regimen of 1.5 MU in 20 min is safe and well tolerated with significantly faster and higher clinical reperfusion rates, more preserved LV systolic function, less atrial and ventricular sustained arrhythmias, and less in-hospital and 1 year mortality rates in acute STEMI.
加速输注链激酶治疗st抬高型心肌梗死的疗效观察
目标:心血管疾病(CVD)被认为是所有国家卫生系统的重要优先事项之一。全世界每年大约有55万例急性心肌梗死首次发作和20万例急性心肌梗死复发。在全球范围内,根据残疾调整生命年评估,缺血性心脏病已成为造成疾病负担的主要因素。目的:探讨加速链激酶治疗急性ST段抬高型心肌梗死的疗效。方法:本描述性研究于2020年8月至2021年2月在白沙瓦Hayatabad医疗中心心脏病科完成。共观察144例患者。所有患者在60分钟内接受150万单位剂量的SK。结果:144例患者的平均年龄和标准差为61±8.19。男性88例(61%),女性56例(39%)。过度加速的链激酶在92例(64%)患者中有效,52例(36%)患者无效。结论:20 min 1.5 MU的SK加速输注方案安全且耐受性良好,临床再灌注率更快、更高,左室收缩功能更完整,房性和室性持续性心律失常更少,急性STEMI住院死亡率和1年死亡率更低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pakistan Heart Journal
Pakistan Heart Journal CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
0.20
自引率
0.00%
发文量
64
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信